Schema of illustrating the proposed trial design. Cohort, group, arm, and zone designation for the proposed study to test safety and immunogenicity of vaccination with the 12 class I major histocompatibility complex-restricted melanoma peptides (Mel12.1) with specified combinations of polyICLC (poly), incomplete Freund’s adjuvant (IFA), CD40 antibody, and with/without CD27 antibody (±)